News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
25.08.2019 20:00:00

Better Buy: Biogen vs. Celgene

Biogen (NASDAQ: BIIB) and Celgene (NASDAQ: CELG) claimed similar market caps earlier this year. That's not the case now, though. In March, Biogen announced that it was halting late-stage clinical studies for its once-promising Alzheimer's disease drug, aducanumab. The biotech's shares collapsed. Celgene's market cap now stands well above Biogen's.But with Celgene months away from being gobbled up by Bristol-Myers Squibb (NYSE: BMY) and Biogen's valuation taking a shellacking, which of these two biotech stocks is the better pick for investors now? Here's how the companies compare in three key areas.Image source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu Celgene Corp.mehr Analysen

03.05.19 Celgene Equal weight Barclays Capital
21.12.18 Celgene Neutral BTIG Research
01.10.18 Celgene Overweight Cantor Fitzgerald
18.06.18 Celgene Buy Standpoint Research
28.02.18 Celgene Buy Stifel, Nicolaus & Co., Inc.

Eintrag hinzufügen

SMI auf Rekordkurs – Notenbanken im Fokus | BX Swiss TV

Aktien in diesem Artikel

Celgene Corp. 89.40 -2.24% Celgene Corp.

Finanzen.net News